

PREPARATIONS OF "ANANTA" LTD in the treatment of the gastroduodenal diseases
associated with *helicobacter pylori*
O.O.Oparin, N.V. Lavrov

The problems of treatment of the gastroduodenal diseases associated with *Helicobacter pylori* are a major problem in modern gastroenterology. According to the latest international recommendations, the leading places in the treatment of this group of diseases belong to antibacterial agents and proton pump inhibitors. These drugs are included in almost all therapy regimens.

Considering the high cost of these drug groups produced by many companies, the medicinal product of "Ananta" company are of interest, being both more affordable in price and similar to drugs that are not inferior in their effect. Among the wide range of medicines produced by this company, we would like to mention a few.

AZICLAR (CLARITHROMYCIN)

1 tablet of Aziclar contains clarithromycin 250 mg or 500 mg.

Clarithromycin belongs to the macrolide group of antibiotics. It acts mainly bacteriostatically, and it is bactericidal in high doses. After oral administration, clarithromycin is quickly and completely absorbed from the gastrointestinal tract. Bioavailability is up to 50%. Food slows down absorption, but does not affect the drug's bioavailability.

Most of the dose is excreted in the form of metabolites with bile. 5-10% is excreted with bile unchanged. When taking 250 mg 2 times a day, 15-20% of the unchanged drug is excreted in the urine, and when taking 500 mg 2 times a day – up to 36%.

Aziclar should not be prescribed in the first trimester of pregnancy, unless the expected benefit to the mother outweighs the potential risk to the foetus. According to the results of some animals trials, it is possible to assume the presence of embryotoxic action in clarithromycin, but these doses are clearly toxic to the mother. The teratogenic effect of clarithromycin in humans has not been described. Clarithromycin excretes into breast milk in significant quantities and must not be prescribed to lactating (breastfeeding) women. If it is necessary to use clarithromycin during this period, breastfeeding must be discontinued.

Aziclar should be used with extreme caution in case of liver and kidney impairment. It is necessary to regularly monitor the activity of liver enzymes in case of chronic liver diseases. The concomitant use of Aziclar with ergot derivatives is contraindicated. When prescribing Aziclar against the background of drugs metabolized by the liver, it is recommended to determine their concentration in the blood plasma. In the case of co-administration with warfarin and other indirect anticoagulants, it is necessary to monitor the prothrombin time. In case of heart diseases, the co-administration of Aziclar with terfenadine, astemizole, cisapride is not recommended.

The drugs, metabolized in the liver with the participation of the cytochrome P450 system (including cyclosporine, disopyramide, alkaloids of cornflowers, lovastatin, midazolam, triazolam, phenytoin, warfarin), may increase their concentration when co-administrated with Aziclar. Clarithromycin slows down the elimination of theophylline and carbamazepine. When Aziclar is co-administrated with theophylline preparations, an increase

in theophylline level in the serum may be observed. As a result theophylline intoxication may occur. When Aziclar is co-administrated with carbamazepine, the effects of the latter may be enhanced. The concomitant use of Aziclar and digoxin can cause an increase in the concentration of digoxin in the blood plasma and an increase in its therapeutic and side effects. Aziclar can increase the effect of hypoglycaemic drugs, therefore, when prescribing Aziclar to patients with diabetes, the level of glucose in the blood should be monitored (risk of hypoglycaemia). As a result of the concomitant use of Aziclar and zidovudine in HIV-infected patients, the constant concentration of zidovudine may decrease, so the drugs must be used with an interval of 1-2 hours. The metabolism of clarithromycin slows down when Aziclar is co-administrated with ritonavir. The concomitant use of Aziclar and omeprazole or ranitidine can cause an increase in their concentration in the plasma, but the dose reduction is not necessary. No interaction of Aziclar with oral contraceptives has been found.

Thus, the medicinal products of "Ananta" can be recommended for inclusion in therapy regimens for patients with gastroduodenal disorders associated with *Helicobacter pylori*.

The reference article is at the link:

<https://anantamedicare.com.ua/ru/specialistam1/izbrannye-voprosy-gastroenterologii-xxi-veka/>